Job
Description
Position:
Cell line development Director / Senior Scientist
Location:
Shanghai or
Fuzhou
Language:
Chinese & English
Accountabilities:
❒ Develop stable CHO recombinant antibody cell lines (including cell banks) and cell cultures for clinic trials and commercial production
❒ As the key member of early PD team, one will cooperate with drug discovery team and also downstream processing people, by using transfection and automatic high throughput selection technology to screening 5~10 top clones as cell bank candidate
❒ Perform cell line stability evaluation and preliminary cell culture process development to deliver stable cell lines (acceptable titer and product quality) to downstream
❒ Follow good lab practice to document the experimental record on laboratory notebook
❒ Experimental equipment’s maintenance, including daily using record, clear, call for repair, etc
❒ Making sure a clear and tidy working environment, including
table and other soft or hard environment management
❒ Arrange and accomplish all job related documents, including:
preparation, writing, translation and filing the documents and reports
❒ Other tasks that may assigned by manager
Qulifications:
❒
Bachelor
degree or above, major in biology or related
❒
3+
years’ experience related to CHO based cell line and cell culture development,
including from transfection, high throughput clones screening, final clone
selection and cell culture process in bio-pharma industry
❒
Hands on
experience with FACS or colonepix2 and CSI (or Cell Metric CLD)
❒
With
strong sense of responsibility, good team spirit
❒
Good
communication, organization and cooperation ability
❒
Skillful
in using office software, such as word and power point
❒
Excellent
in reading and writing level both in Chinese and English
TAYU-BIOTECH
Introduction:
TAYU Biotech group was established in
September 2016, which is committed to develop innovative immunotherapy drug in
China founded by Professor Chen Lieping who is a global famous immunologists
and oncologists.
Professor Chen Lieping is
the world’s leading investigator in the characterization of cell surface
co-stimulatory and co-inhibitory molecules that modulate immune responses. He
is professor of immunobiology, of
dermatology, and of medicine (medical oncology) at Yale School of Medicine and
director of the cancer immunology program at the Yale Cancer Center. Professor Chen is the first scientist to apply
co-stimulation as a mean for cancer immunotherapy. His laboratory discovered
immune suppressive function of the B7-H1 (PD-L1)/PD-1 pathway in cancer and first
demonstrated using antibody to block this pathway to enhance tumor immunity for
the therapy of cancer. The anti-PD-1 and anti-PD-L1 has been well recognized as
the most safe and effective drugs for the therapy of cancer so far.
With a rich experienced R&D team, TAYU is developing anti-tumor drug including immune checkpoint
inhibitors, co-stimulus antibodies, dual specificity antibodies and biomarker
etc. TAYU group will strive to grow into a top biopharmaceuticals group that
covers research, transformation and manufacture in the future.
Contact
information:
Address: 8-2 Dongdan Santiao, Dongcheng
district, Beijing, China
Tel: +86 10 67177097
E-mail:clara@tayubiotech.com